Amphastar Pharmaceuticals Files 8-K on Corporate Matters
Ticker: AMPH · Form: 8-K · Filed: 2025-06-04T00:00:00.000Z
Sentiment: neutral
Topics: corporate-governance, filing-update
Related Tickers: AMPH
TL;DR
AMPH filed an 8-K covering corporate changes and shareholder votes.
AI Summary
On June 2, 2025, Amphastar Pharmaceuticals, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. The company, incorporated in Delaware with its principal executive offices in Rancho Cucamonga, CA, operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates potential changes in Amphastar's corporate structure or governance, which could impact its operational direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is procedural and relates to corporate governance rather than immediate financial performance or significant operational shifts.
Key Players & Entities
- Amphastar Pharmaceuticals, Inc. (company) — Registrant
- June 2, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rancho Cucamonga, CA (location) — Address of principal executive offices
- 909-980-9484 (phone_number) — Registrant's telephone number
FAQ
What specific amendments were made to Amphastar Pharmaceuticals' Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information.
What matters were submitted to a vote of Amphastar Pharmaceuticals' security holders?
The filing states that matters were submitted to a vote, but the nature of these matters is not specified in the provided text.
What financial statements and exhibits are included in this 8-K filing?
The filing mentions the inclusion of financial statements and exhibits, but their specific content is not detailed in the summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 2, 2025.
Where are Amphastar Pharmaceuticals, Inc.'s principal executive offices located?
Amphastar Pharmaceuticals, Inc.'s principal executive offices are located at 11570 Sixth Street, Rancho Cucamonga, CA 91730.
From the Filing
0001297184-25-000036.txt : 20250604 0001297184-25-000036.hdr.sgml : 20250604 20250603204619 ACCESSION NUMBER: 0001297184-25-000036 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250602 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250604 DATE AS OF CHANGE: 20250603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amphastar Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001297184 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 330702205 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36509 FILM NUMBER: 251021627 BUSINESS ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 909-980-9484 MAIL ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 8-K 1 amph-20250602x8k.htm 8-K _ 0001297184 false --12-31 0001297184 2025-06-02 2025-06-02   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2025     Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter)       ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Delaware   001-36509   33-0702205 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) ​ ​ ​ 11570 6 th Street   ​ Rancho Cucamonga , CA   91730 (Address of principal executive offices) ​ (zip code) ​ ( 909 ) 980-9484 (Registrant’s telephone number, including area code)   ​ ​     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ​ ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ​ ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ​ ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ​ ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​   Securities registered pursuant to Section 12(b) of the Act: ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share AMPH The NASDAQ Stock Market LLC ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ ​ ​ ITEM 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. ​ At the 2025 Annual Meeting of Stockholders of Amphastar Pharmaceuticals, Inc. (the “Company”) held on June 2, 2025 (the “Annual Meeting”), the stockholders of the Company voted on and approved amendments to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) (i) to re